Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
7.80
-0.04 (-0.51%)
At close: Dec 5, 2025, 4:00 PM EST
7.65
-0.15 (-1.92%)
After-hours: Dec 5, 2025, 6:00 PM EST

Kyverna Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-160.99-127.48-60.37-28.89-26.35
Depreciation & Amortization
1.992.131.711.050.59
Loss (Gain) From Sale of Assets
0.04---0.02
Loss (Gain) From Sale of Investments
-7.76-7.66-1.12-0.28-
Stock-Based Compensation
8.768.362.220.930.25
Other Operating Activities
2.842.541.721.417.83
Change in Accounts Payable
-6.910.744.080.680.01
Change in Unearned Revenue
----7.03-5.66
Change in Other Net Operating Assets
4.137.12-0.66-3.981.16
Operating Cash Flow
-157.25-114.25-52.41-36.11-22.16
Capital Expenditures
-0.54-2.21-0.62-0.77-1.29
Investment in Securities
87.58-158.7-8.16-13.33-
Investing Cash Flow
86.52-160.9-8.79-14.1-1.29
Long-Term Debt Repaid
--0.96-0.78-0.25-0.04
Net Debt Issued (Repaid)
-0.97-0.96-0.78-0.25-0.04
Issuance of Common Stock
1.69341.430.650.180.03
Other Financing Activities
-0.41-3.36-1.65--
Financing Cash Flow
0.21337.1158.1211.8872.52
Net Cash Flow
-70.5161.96-3.08-38.3349.08
Free Cash Flow
-157.78-116.46-53.03-36.88-23.44
Free Cash Flow Margin
----525.00%-414.50%
Free Cash Flow Per Share
-3.65-3.04-78.72-80.97-88.17
Cash Interest Paid
0.070.140.190.070
Levered Free Cash Flow
-95.63-69.56-29.74-23.54-
Unlevered Free Cash Flow
-95.58-69.47-29.63-23.5-
Change in Working Capital
-2.787.863.42-10.33-4.49
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q